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doi:10.1016/j.ejvs.2011.02.024Abstract Objectives: Management of proximal common carotid artery (pCCA) lesions is infre-
quently reported. We described open and endovascular treatment with regard to the neurolog-
ical outcome and patency in patients suffering from atherosclerotic pCCA lesions.
Methods: Data were collected prospectively and analysed in a retrospective manner.
Results: From November 1991 to January 2010, 52 procedures, 24 surgical (11 bypasses, 12
transpositions and retrograde endarterectomy) and 28 endovascular (13 open transcervical
and 15 transfemoral stent implantations) were performed (40.4% female, mean age 62.3 years,
65.4% left-sided). A total of 25 lesions (48.1%) were symptomatic (13 stenoses and 12 occlu-
sions); 27 (51.9%) lesions were asymptomatic (22 stenoses and five occlusions). Two bypasses
occluded within 30 days. Two early ipsilateral strokes were observed (3.8%). There was one
perioperative death due to myocardial infarction after transcervical stent (1.9%). Mean
follow-up was 61 months. In one transposition and two stent implantations, late redo interven-
tions were performed. Fourteen of 48 patients died during follow-up.
Conclusion: pCCA repair for atherosclerotic lesions is associated with a substantial periopera-
tive risk (combined stroke/death rate: 5.7%). Endovascular intervention is the preferred inva-
sive treatment option in patients suffering from stenotic pCCA lesions. In cases of pCCA
occlusion, open surgery is a valid alternative. Late survival in patients suffering from pCCA
lesions is poor.
ª 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.The proximal common carotid artery (pCCA) is the second
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Treatment of Common Carotid Artery Lesions 729extrathoracic procedures avoiding thoracotomy became
popular in the 1960s.57 In the 1980s, percutaneous trans-
luminal angioplasty (PTA) was first described.8,9 In the
1990s, stent-supported PTA (sPTA) extended the thera-
peutic armamentarium and improved the long-term
patency of endovascularly treated SAT lesions.1013 The
aim of this retrospective study was to compare safety and
efficacy of the surgical and endovascular treatment of
pCCA lesions with regard to neurological outcome and
patency.Patients and Methods
Patients were recruited at a university-based tertiary care
centre. Patient data were entered prospectively in a dedi-
cated data base and analysed in a retrospective manner.
Data were prepared according to the suggested Reporting
Standards by the European Society for Vascular Surgery
(ESVS).14
Indication for pCCA revascularisation
Revascularisation of symptomatic pCCA lesions was per-
formed for CCA occlusion or stenosis of >70%. Asymptom-
atic pCCA lesions were treated in case of CCA stenosis >80%
lumen reduction. Asymptomatic occlusions were treated if
the ipsilateral internal carotid artery (ICA) had a high-grade
(>80%) stenosis or if the contralateral ICA was occluded.
This was in accordance with previous publications.15 There
are currently no guidelines available from ESVS or Society
for Vascular Surgery (SVS) regarding the management of
pCCA lesions.14
Preoperative examination
The preoperative evaluation was performed by vascular
surgeons and an independent neurologist. Prior to surgery,
the medical history was evaluated and a physical exami-
nation was performed. Imaging before surgery or endovas-
cular treatment included colour-coded duplex sonography
(DS), magnetic resonance angiography (MRA), computed
tomography angiography (CTA) and/or digital subtraction
angiography (DSA) of the aortic arch vessels. Most patients
received at least two different imaging studies. Preopera-
tive brain imaging was routinely performed using either CT
or magnetic resonance imaging (MRI).
Technique of open pCCA revascularisation
Subclavian artery (SA)-to-carotid bypasses and CCA-to-SA
transpositions were carried out under general anaesthesia.
We used the lateral supraclavicular approach for bypasses
and the medial approach in between the bellies of the
sternocleidomastoid muscle for transpositions.16 In patients
with high-grade ipsilateral ICA stenosis, a bypass was the
preferred technique. After standard endarterectomy of the
ICA, the SA-to-carotid bypass was anastomosed to the
endarterectomised segment. Completion angiography was
done routinely.Retrograde ring-stripper endarterectomy of the pCCA
was performed via standard exposure of the CCA. After
clamping of the distal CCA proximal to the carotid bifur-
cation, a longitudinal incision of the CCA was performed.
After transection of the intima of the CCA, the ring-stripper
was introduced into the subintimal cleavage plane. When
the ring-stripper reached the aortic arch, the endarterec-
tomised core was removed via the arteriotomy. Completion
angiography was performed via a pigtail catheter posi-
tioned in the aortic arch.
Technique of hybrid endovascular procedures
Open retrograde stenting of the pCCA was performed in an
angiography-compatible operating room. After cutdown to
the CCA under local anaesthesia, the artery was clamped
and punctured proximal to the carotid bifurcation. The
position of the clamp allowed blood flow between the
external carotid artery (ECA) and the ICA, and prevented
embolisation into the brain during angioplasty. After
traversing the stenosis with a standard 0.035-inch guide
wire, the lesion was predilated and stented by balloon- or
self-expandable stents. Balloon-expandable stents were
used for ostial stenoses. Self-expandable stents were used
in the proximal body of the CCA. The size of the stents was
chosen according to the diameter of the CCA beyond the
stenosis. A <30% residual stenosis was judged as a success-
ful intervention. After removing the sheath and the arterial
clamp, the CCA was flushed extensively. In cases with
concomitant ICA stenosis, a standard carotid endarterec-
tomy (CEA) was performed prior to the pCCA repair. As the
CCA lesion was treated by endovascular means, these cases
were defined as endovascular.
Technique of percutaneous procedures
sPTA procedures were performed in the angio suite under
local anaesthesia with femoral approach in all cases. Indi-
cation for and size of self-expandable and balloon-
expandable stents were the same as for hybrid procedures.
A <30% residual stenosis with completion angiography was
judged as a successful intervention. Embolic protection
devices were used at the discretion of the vascular surgeon.
The technical details of CCA revascularisation were
described previously.8,10,12,17,18 The type of intervention
was at the discretion of the vascular surgeon.
Postoperative examination
All patients underwent post-procedural examination by an
independent neurologist. In surgical cases, laryngoscopy
was routinely performed for detection of recurrent laryn-
geal nerve injuries. Fluoroscopy was undertaken in all
surgical cases to rule out phrenic nerve palsies.
Long-term follow-up
After discharge, patients were routinely evaluated in the
outpatient department and tracked with phone calls, if
they missed a scheduled appointment for more than 6
months. They were seen every 3 months during the first
730 K. Linni et al.year and annually thereafter. Colour-coded DS was carried
out at every postoperative visit. High-grade pCCA stenosis
was suspected if the peak systolic velocity exceeded
300 cm s1, or if the end-diastolic velocity was
>100 cm s1. MRA, CTA and/or DSA of the aortic arch
vessels were performed only if there was suspicion of
a significant recurrent stenosis of the pCCA reconstruction
or the need for repair of another supraaortic artery.
Statistical analysis
Data were prepared as suggested by the guidelines.14
Statistical analysis was performed calculating each inter-
vention individually. Data are presented as percentage and
means with ranges. Survival rates and patency estimations
were obtained using the KaplaneMeier analysis (SPSS, Chi-
cago, IL, USA). A value of p < 0.05 (log rank test) was
considered significant.ResultsPatient demographics and risk factors (Table 1)
From November 1991 until January 2010, 52 pCCA inter-
ventions (endovascular group n Z 28, surgical group
nZ 24) in 48 patients (40.4% female, mean age 62.3 years,
range, 40.9e81.4 years) were carried out. During the same
time period, more than 3400 CEAs have been performed in
our department. pCCA lesions were left in 65.4% of cases.
All lesions were atherosclerotic. Patient characteristics and
risk factors were equally distributed between the surgical
and endovascular groups.
Preoperative neurological symptoms (Table 2)
In 51.9% (27/52) of cases, pCCA lesions were asymptomatic
(21/28 endovascular, 6/24 surgical; p Z 0.007).
Nearly half (48.1%, 25/52) of cases had ipsilateral
central neurological symptoms preoperatively. In the
surgical group, 75% (18/24) and in the endovascular group,
25% (7/28) were symptomatic, respectively. The most
common preoperative neurological symptoms were tran-
sient ischaemic attacks (TIAs, 17/52, 32.7%), followed byTable 1 Patient demographics and risk factors in 52 pCCA case
Parameters Endovascular group (n Z 28) S
Female 10 (35.7)
Male 18 (64.3)
Left-sided lesions 17 (60.7)




Coronary artery disease 8 (28.6)
Diabetes 8 (28.6)
pCCA: proximal common carotid artery, n.s.: not significant.amaurosis fugax (7/52, 13.5%) and minor stroke (1/52,
1.9%), respectively.
Preoperative antiaggregation
All patients were treated without cessation of anti-throm-
botic therapy; 80.8% (42/52) of cases were under ace-
tylsalicylic acid (ASA) (100 mg day1), 13.5% (7/52) of
patients were treated with ASA (100 mg day1) and clopi-
dogrel (75 mg day1) mainly because of previous coronary
stenting and 5.8% (3/52) of patients received clopidogrel
(75 mg day1) only because of ASA intolerance. No patient
received anticoagulation.
Anatomy of the supraaortic vessels in 52 pCCA
cases
Two-thirds (67.3%, 35/52) of patients revealed a high-grade
(>80%) pCCA stenosis (left-sided n Z 22, asymptomatic
nZ 22, symptomatic nZ 13); an equal percentage (24/35,
69%) stenoses were in the proximal body of the CCA. Nearly
one-third (11/35, 31%) stenoses were ostial; 32.7% (17/52) of
patients revealed CCA occlusion (left-sided n Z 12, symp-
tomatic n Z 12, asymptomatic n Z 5); 71.1% (37/52) of
patients revealed an additional SAT lesion; 17.3% (9/52) of
patients revealed a concomitant ipsilateral significant ICA
stenosis (left-sided n Z 6, asymptomatic n Z 6, symptom-
atic nZ 3). One patient with asymptomatic pCCA occlusion
also had an asymptomatic contralateral ICA occlusion.
Surgical and endovascular procedures (Table 3)
There were 52 interventions (49 for primary unilateral pCCA
lesions, three for recurrent unilateral lesions) in 48
patients. Twenty-eight procedures (53.8%) were endovas-
cular and 24f (46.2%) were surgical, respectively.
The most commonly performed procedure was sPTA
(28.8%, 15/52).
Twelve primary and three recurrent pCCA lesions were
treated by sPTA. Recurrent pCCA stenoses occurred 5, 12 and
19 months after primary intervention (one after trans-
position for CCA occlusion, two after sPTA for CCA stenosis
each), respectively. In 60% (9/15) of sPTA procedures, four
self-expandable Astron stents (Biotronik GmbH, Berlin,
Germany), three self-expandable Sinus stents (Optimed,s.
urgical group (n Z 24) Both groups (n Z 52) p value
11 (45.8) 21 (40.4) n.s.
13 (54.2) 31 (59.6) n.s.
17 (70.8) 34 (65.4) n.s.
3.3(45.1e81.4) 62.3 (40.9e81.4) n.s.
19 (79.1) 40 (76.9) n.s.
15 (62.5) 34 (65.4) n.s.
11 (45.8) 25 (48.0) n.s.
9 (37.5) 17 (32.7) n.s.
7 (29.2) 15 (28.8) n.s.
Table 2 Preoperative central neurological symptoms in 52 pCCA cases (Reporting Standards for Cerebrovascular Disease
published by ESVS14).
Neurological symptoms Endovascular group (n Z 28) Surgical group (n Z 24) Both groups (n Z 52) p value
TIA 2 (7.1) 15 (62.5) 17 (32.7) n.s.
Amaurosis fugax 4 (14.3) 3 (12.5) 7 (13.5) n.s.
Minor stroke 1 (3.6) 0 (0.0) 1 (1.9) n.s.
Asymptomatic 21 (75.0) 6 (25.0) 27 (51.9) 0.007
pCCA: proximal common carotid artery, TIA: transient ischaemic attack, n.s.: not significant.
Treatment of Common Carotid Artery Lesions 731Ettlingen, Germany) and two self-expandable Absolute
stents (Guidant, USA) were implanted, respectively. In 40%
(6/15) of sPTAprocedures, three balloon-expandable Palmaz
stents (Johnson and Johnson Interventional Systems,
Warren, NJ, USA) and three balloon-expandable Palmaz
Genesis stents (Cordis, Miami, FL, USA) were inserted. The
mean stent length was 4 cm (range, 2.5e5 cm) and the mean
stent diameter was 8 mm (range, 8e10 mm). In 40% (6/15) of
sPTA procedures, a distal embolic protection device (Angio-
Gard, Cordis, Miami, FL, USA) was used (all for primary pCCA
stenoses).
In 25% (13/52) of patients, open retrograde stent implan-
tation was carried out. All procedures were done for primary
stenoses (symptomatic n Z 7, concomitant CEA n Z 3). In
61.5% (8/13) of open retrograde stenting, three self-
expandable Sinus stents, three self-expandable Absolute
stents and two self-expandable Astron stents were used,
respectively. In 38.5% (5/13) of open retrograde stenting,
three balloon-expandable Palmaz stents and two balloon-
expandablePalmazGenesis stentswereused.Themeanstent
length and stent diameter were equal to sPTA procedures.
In 23% (12/52) of cases, CCA-to-SA transposition was
carried out. All transpositions were for symptomatic pCCA
lesions (stenoses n Z 6, occlusions n Z 6).
In 21.1% (11/52) of cases, SA-to-carotid bypass was
carried out (symptomatic n Z 6, asymptomatic n Z 5,
occlusions nZ 10, stenosis nZ 1, concomitant CEA nZ 6).
Bypass graft material was polytetrafluoroethylene (PTFE,
n Z 6) or Dacron (Hemashield; Meadox Medicals, Inc,
Oakland, NJ, USA) (n Z 4). Reversed greater saphenous
vein was used in one case. The mean diameter of synthetic
grafts was 7 mm (range, 6e8 mm).
One patient (1.9%, 1/52) with asymptomatic occlusion of
the left CCA and contralateral occlusion of the ICA was
treated by retrograde ring-stripper endarterectomy.Table 3 Endovascular and surgical procedures in 52 pCCA case
Procedures Endovas
sPTA 15 (53.6
Open retrograde stenting without CEA 10 (35.7
Open retrograde stenting with CEA 3 (10.7
CCA-to-SA transposition
SA-to-Carotid bypass with CEA
SA-to-Carotid bypass without CEA
Retrograde ring-stripper endarterectomy
pCCA: proximal common carotid artery, CCA: common carotid arter
SA: subclavian artery, CEA: carotid endarterectomy.Postoperative antiaggregation
A little more than half (59.6%, 31/52) of patients received
ASA (100 mg day1) as single therapy; 34.6% (18/52) of
patients received dual antiaggregation with ASA (100 mg
day1) and clopidogrel (75 mg day1). In these cases, clo-
pidogrel was given either for 3 months postoperatively
(n Z 11) or for a longer time period (i.e., due to coronary
stenting, nZ 7). In 5.8% (3/52) of cases, the postoperative
antiaggregation was by clopidogrel (75 mg day1) only.Perioperative complications and outcome
There was no statistically significant difference between
both treatment groups concerning overall perioperative
complication rates (p Z 0.0514).
For the entire patient cohort, the combined perioper-
ative death/stroke rate and overall perioperative compli-
cation rate was 5.7% (3/52) and 13.5% (7/52), respectively.
In the surgical group, the perioperative death and stroke
rates were 0% and 4.2% (1/24); the overall perioperative
complication rate was 20.8% (5/24).
In the endovascular group, the perioperative death and
stroke rates were 3.6% (1/28) each; the overall perioper-
ative complication rate was 7.1% (2/28).
Ninety-six percent of symptomatic patients (24/25) were
neurologically asymptomatic at discharge. One patient (4%)
died due to myocardial infarction 5 days after open retro-
grade stent implantation for symptomatic CCA stenosis. In
two primarily asymptomatic stenoses (7.4%), we observed
an early ipsilateral non-fatal ischaemic stroke within 30
days of intervention: one patient during left-sided primary
sPTA (without protection device) and one patient due to
bypass occlusion 2 days after a right-sided Dacron bypasss.
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732 K. Linni et al.grafting with concomitant CEA. In 8.2% (2/24) of cases,
postoperative cranial nerve injuries (CNIs) were diagnosed
in the surgical group: one recurrent laryngeal nerve injury
after bypass grafting and one hypoglossal nerve injury after
bypass grafting. In addition, one Horner’s syndrome after
transposition was observed. All CNIs were transient and
resolved 4 weeks to 5 months postoperatively. In 4.2% (1/
24) of the surgical group, a lymphatic leak was observed.
This case could be handled conservatively with cessation of
the lymphatic secretion 18 days postoperatively.
Technical success, patency, neurologic outcome
and survival
Primary technical success rate was 100%. No patient was
lost to follow-up.
Mean follow-up time was 61 months (range, 0.9e218
months) for both groups, 50.5 months (range, 0.9e101
months) for the endovascular group and 72.9 months
(range, 1e218 months) for the surgical group, respectively.
Patency
Two bypasses occluded within 30 days after operation.
There were no late bypass occlusions. In three cases (5.8%),
we performed late redo sPTA because of high-grade (>80%)
asymptomatic recurrent stenosis. In one patient, right-
sided high-grade stenosis of the pCCA was detected by DS
and CTA 19 months after transposition for symptomatic
occlusion. In two patients, right-sided >80% stenosis of the
pCCA was detected 5 and 12 months after sPTA. The
patency probabilities were 89.3% (confidence interval (CI):
5.85%) for endovascular surgery and 91.7% (CI: 6.5%) for
open treatment at 5 years with no statistical significance
between both groups (log rank: p Z 0.741).
Late neurologic outcome
One primarily symptomatic patient (1.9%) suffered a late
non-fatal ipsilateral ischaemic stroke during left-sided CEA
16 months after ipsilateral transposition for pCCA stenosis.
Patient survival
There was one perioperative death due to myocardial
infarction (open retrograde sPTA). Fourteen of 48 patients
(29.2%, endovascular group n Z 8, surgical group n Z 6)
died during follow-up. The most common cause of death
was ischaemic cardiac disease (57.1%). Five-year survival
was 79.6% after endovascular surgery and 70.7% after open
intervention. There was no statistically significant differ-
ence between both groups (Log rank: p Z 0.335).
Discussion
Our study described the neurological and overall outcome
of patients with pCCA pathology undergoing either endo-
vascular or open surgical intervention. There has been no
report so far dedicated exclusively to this entity. All reportson pCCA pathology are within larger series including repair
of all SAT lesions.
At the beginning of the study period, all our patients
underwent open surgery. Yet, it has become common
practice in our department to offer primary endovascular
procedures in patients suffering from pCCA lesions to
reduce complications, such as CNI and lymphatic damage,
and to shorten hospital stay. The only indication to refrain
from endovascular management was the presence of CCA
occlusion.
Takach et al. in 2005 reported on 391 consecutive
patients, who were treated from 1966 to 2004 for a single-
vessel brachiocephalic disease.19 Only a small part of this
large series were CCA lesions (n Z 17, 4.3%). Takach et al.
did not make a subgroup analysis of the CCA group and
failed to describe the surgical and endovascular results
within that group. Furthermore, it is difficult to draw any
conclusion from a study, which comprises for a large part SA
lesions because these are more benign in natural history
and treatment compared with CCA lesions.
Our study shows that perioperative stroke and death
rates were not significantly different between both treat-
ment groups. In the endovascular group, one patient died
due to myocardial infarction 5 days after open retrograde
stenting for symptomatic pCCA stenosis. This patient pre-
sented with known ischaemic heart disease, and this was
not believed to be a contraindication for the carotid
procedure. One patient suffered a major ipsilateral stroke
during sPTA without a protection device, which were then
not available. Previous publications reported similar
mortality rates for open15,20,21 and endovascular22 treat-
ment. Use of embolic protection devices is not reported in
literature on a routine basis. Although these devices have
been available in recent years, their use in pCCA lesions is
controversial, mainly due to the fact that ostial lesions may
not be suitable to be traversed with these devices. A major
advantage of endovascular procedures compared with
surgical treatment of CCA lesions is the remote access of
the intervention resulting in decreased neck complication
rates, such as CNI damage or lymphatic leak. In our open
surgical group, 12.5% (3/24) suffered from CNI and 4.2% (1/
24) from damage of the thoracic duct. Although all
complications could be handled conservatively, they cause
significant discomfort to the patient.
According to the literature, open retrograde stenting has
the potential advantage of embolic protection during the
intervention reducing major peri-procedural neurological
events.23,24 Sullivan et al. concluded that difficult CEAs and
synchronous retrograde stenting in patients suffering from
tandem lesions should be treated with caution because of
poor outcome following combined treatment of ICA and
CCA lesions.12 In our study group, endovascularly treated
tandem lesions (3/28, 10.7%) were without complications
and patent at a mean follow-up time of 53 months.
The most commonly cited argument to prefer extra-
thoracic surgery overendovascular treatment is theexcellent
long-term patency of bypasses and transpositions. Takach
et al. reported a significantly better midterm freedom from
graft failure in the bypass group (92.7%) compared with the
sPTA group (83.9%, pZ 0.03) 5 years after the procedure.19
Berguer et al. reported on a 16-year experience with
182 extrathoracic brachiocephalic reconstructions with
Treatment of Common Carotid Artery Lesions 733cumulative primary patency rates of 91% and 82% at 5 and 10
years, respectively.15 Such long-time results in a large study
population have not been reported for endovascular therapy.
Yet, midterm results of endovascular treatment may concur
with surgical outcomes. Paukovits et al. reportedon153pCCA
lesions treatedby sPTA (nZ 108) or PTA (nZ 45). Cumulative
primarypatency rateswere97.9%at 1 yearand82%at 4 years,
respectively, without statistically significant difference
between sPTA and PTA.21 In our study, patency probabilities
were identical between open surgery and endovascular
therapy (log rank: pZ 0.741).
Survival rates are poor in patients suffering from SAT
lesions, mainly because of ischaemic cardiac disease. Ber-
guer et al. reported survival rates of 72% and 41% at 5 and
10 years, respectively.15 Archie reported survival rates of
64% and 28% at 5 and 10 years, respectively, in patients
undergoing extrathoracic bypass grafting for symptomatic
severe CCA occlusive disease.25 In our study, survival
probability was poor even though cardiac disease was only
present in one-third of the patients at the time of inter-
vention. During follow-up, most of the patients died due to
cardiac disease. We assume, in accordance with literature
that, in patients suffering from SAT lesions, the athero-
sclerotic process seems more aggressive and leads to earlier
mortality compared with other groups of vascular disease.
In the light of poor long-term survival of patients with
SAT lesions and the unknown natural history, it is a constant
debate how to treat asymptomatic CCA lesions. In 1999 Cull
et al. reported on asymptomatic patients with CCA occlu-
sion and patent ICA, which were treated conservatively.26
The authors concluded that their patients usually
remained asymptomatic with a long-term patency of the
ICA up to 8 years. There are no guidelines concerning this
issue. It has been our practice to treat CCA lesions in the
same manner as ICA lesions.
Our study has several drawbacks. One is the difficulty of
therapy selection in this patient group, as both management
options were not available over the entire study period.
Endovascular therapy has become the preferred option
during the secondhalf of the studyperiod,mainly for stenotic
lesions. Our study is retrospective, leading to a significant
differenceofpreoperatively asymptomatic patients between
theendovascular and surgical group (75% vs. 25%). This should
be overcome by prospective studies in the future.Conclusion
pCCA repair for atherosclerotic lesions can be achieved with
a combined perioperative death/stroke rate of 5.7%. The
endovascular approach should be the invasive treatment of
choice in these patients with stenotic lesions, irrespective of
the preoperative neurologic status. If an endovascular repair
is impossible because of anatomical or technical reasons, an
operative extrathoracic repair seems a valid alternative. In
patients suffering from pCCA lesions, the neurological
outcome and the patency probability for endovascular and
surgical procedures are equal but the late survival is poor.
Because pCCA lesions are rare and much less frequently
reported compared with ICA lesions, larger multicentre
trials would be necessary to answer questions concerning the
best treatment modality for asymptomatic patients.Conflict of Interest/Funding
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